Formulation, Optimization and Evaluation of an Ion-Activated Ocular In-Situ Gel of Timolol Maleate Using Natural Gelling Agents (Sodium Alginate and Gellan Gum) for Sustained Glaucoma Therapy

References

[1] El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm. 2002;241(1):47–55.

[2] Varshosaz J, Tabbakhian M, Salmani Z. Designing of a thermosensitive chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin. Open Drug Deliv J. 2008;2:61–70.

[3] Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.

[4] Global prevalence and burden of glaucoma: leading cause of irreversible blindness (76 million in 2020; 111.8 million projected by 2040). J Glob Health. 2024;14:04252.

[5] Sonawane SD, Patil RY, et al. In situ gel: a novel approach in sustained ophthalmic drug delivery. Int J Pharm Sci Res. 2013.

[6] Patil S, Kumar A. Ocular in situ gels: development, evaluation and advantages. Int J Pharm Investig. 2014.

[7] Paul S, et al. Sodium alginate: a versatile ion- and pH-triggered biopolymer for in situ gelling drug delivery. 2017.

[8] Stubb J, et al. Gelation properties and pharmaceutical applications of alginate and gellan gum. 2019.

[9] Timolol maleate ophthalmic solution: prescribing information (TIMOPTIC 0.25% and 0.5%). Merck / FDA DailyMed.

[10] Timolol maleate: non-selective β-adrenergic blocker for glaucoma – pharmacology and clinical use. Goodman & Gilman's Pharmacological Basis of Therapeutics. 2018.

[11] Balasubramaniam J, Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin. Drug Deliv. 2003;10(3):185–91.

[12] Patil S, et al. Formulation and evaluation of ocular in situ gel by cold method. 2015.

[13] Higuchi T. Mechanism of sustained-action medication: rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–49.

[14] Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.

[15] Rathore KS. In situ gelling ophthalmic drug delivery system: an overview. Int J Pharm Pharm Sci. 2010–2011.

[16] Jagdale S, et al. Compatibility study of timolol maleate with polymers by FTIR and DSC. 2016.

[17] Erol S, Karatas A. Development of a triple-polymer ophthalmic in situ gelling system of berberine HCl. 2025.

[18] Ozlem C, et al. Thermosensitive mucoadhesive timolol maleate ophthalmic in situ gel using poloxamers with chitosan/CMC. 2024.

[19] Xu Y, et al. Ion-sensitive in situ ophthalmic gel of brimonidine tartrate based on gellan gum: enhanced ocular retention and bioavailability. 2023.

[20] Lokapur V, et al. Proniosomal in situ gel of timolol maleate for glaucoma. 2022.

[21] Bharath S, et al. pH-triggered in situ gel of brimonidine tartrate using Carbopol/HPMC. 2020.

[22] Kurniawansyah IS, et al. Optimization of ophthalmic in situ gel using 3² factorial design (Poloxamer 407/HPMC). 2020.

[23] Prabhu P, Koland M. Thermosensitive in situ gel of ofloxacin using Poloxamer 407 and HPMC/PVA. 2019.

[24] Al-Bazzaz FY, et al. Thermosensitive in situ ocular gel of ciprofloxacin using poloxamer 407 and HPMC. 2018.

[25] Nagesh C, et al. pH-sensitive in situ ocular gel of ciprofloxacin. 2017.

[26] Makwana SB, et al. Formulation and characterization of in situ ophthalmic gel of ciprofloxacin hydrochloride using sodium alginate and HPMC. 2015.

[27] Mandal S, et al. In situ gel-forming ophthalmic system of ciprofloxacin using sodium alginate (ion-activated). 2012.

[28] Kavitha K, Rajas NJ. Sustained-release in situ ophthalmic gel of levofloxacin hemihydrate using gelrite. 2011.

[29] Cao F, et al. In situ gelling ophthalmic system of azithromycin using poloxamer and Carbopol 974P. 2010.

[30] Gratieri T, et al. Thermosensitive mucoadhesive poloxamer/chitosan in situ gel for prolonged ocular retention. Eur J Pharm Biopharm. 2010.

[31] Qian Y, et al. Thermosensitive in situ gel of methazolamide for ocular delivery. 2010.

[32] Al-Kassas RS, El-Khatib MM. Controlled-release ophthalmic in situ gels of ciprofloxacin using carbopol and alginate. 2009.

[33] Mohan EC, et al. pH-, thermo- and ion-responsive in situ ocular gels of ciprofloxacin. 2009.

[34] Mansour M, et al. Thermosensitive in situ gel of ciprofloxacin hydrochloride using poloxamers. 2008.

[35] Gupta H, et al. Thermo- and pH-triggered in situ gel of timolol maleate using Pluronic F-127 and chitosan. 2007.

[36] Sultana Y, et al. Ion-activated in situ ophthalmic gel of pefloxacin mesylate using gellan gum. 2006.

[37] Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release. 2007;122(2):119–34.

[38] Tham YC, et al. Global glaucoma prevalence by region and type (POAG/PACG). Ophthalmology. 2014;121(11):2081–90.

@article{1719986,
      author = {Prince Pandey, Vishal Kumar Singh},
      title = {Formulation, Optimization and Evaluation of an Ion-Activated Ocular In-Situ Gel of Timolol Maleate Using Natural Gelling Agents (Sodium Alginate and Gellan Gum) for Sustained Glaucoma Therapy},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {1},
      pages = {2233-2246},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1719986.pdf},
      abstract = {Conventional ophthalmic eye drops suffer from poor ocular bioavailability, typically below five percent, owing to rapid precorneal drainage, tear turnover and nasolacrimal clearance, which shorten the residence time of the drug and necessitate frequent dosing. The present study was undertaken to formulate, optimize and evaluate an ion-activated ocular in-situ gel of the antiglaucoma β-blocker timolol maleate using the naturally derived, ion-sensitive gelling polymers sodium alginate and gellan gum, with the aim of prolonging precorneal residence time, sustaining drug release and reducing dosing frequency. Nine formulations (F1–F9) were prepared by the cold (dispersion) method with the drug fixed at 0.5% w/v and varying polymer and calcium chloride concentrations. Preformulation FTIR and DSC studies confirmed the absence of any drug–polymer interaction. All formulations were transparent, of ocular-compatible pH (6.6–7.3), exhibited pseudoplastic flow and underwent immediate sol-to-gel transition on contact with simulated tear fluid, with viscosity rising sharply after gelation. Drug content was uniform (96.2–101.4%). In-vitro release across F1–F9 was sustained over 8–12 hours; the optimized batch F7 released 92% of drug in 12 hours without any burst effect, best fitting the Korsmeyer–Peppas model (R² = 0.989, n = 0.67) indicative of non-Fickian (anomalous) transport. Ex-vivo corneal permeation of F7 was gradual and sustained, reaching 82.16% at 8 hours, markedly outperforming a marketed solution. The optimized formulation remained physically and chemically stable over three months under ICH long-term and accelerated conditions. The developed natural-polymer ion-activated in-situ gel is a promising, patient-friendly alternative to conventional timolol eye drops for glaucoma management.},
      keywords = {Ocular In-Situ Gel, Timolol Maleate, Sodium Alginate, Gellan Gum, Ion-Activated Gelation, Glaucoma, Sustained Release, Precorneal Residence Time.},
      month = {July},
      doi = {https://doi.org/10.64388/IREV10I1-1719986}
  }